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Design and efficacy of bioactive drugs is restricted by their (in)ability to traverse cellular membranes.
Therapy resistance, a major cause of ineffective cancer treatment, is frequently due to suboptimal
intracellular accumulation of the drug. We report a molecular mechanism that promotes trans-membrane
movement of a stereotypical, widely used anti-cancer agent to counteract resistance. Well-defined lipid
analogues adapt to the amphiphilic drug doxorubicin, when co-inserted into the cell membrane, and
assemble a transient channel that rapidly facilitates the translocation of the drug onto the intracellular
membrane leaflet. Molecular dynamic simulations unveiled the structure and dynamics of membrane
channel assembly. We demonstrate that this principle successfully addresses multi-drug resistance of
genetically engineeredmouse breast cancermodels. Our results illuminate the role of the plasmamembrane
in restricting the efficacy of established therapies and drug resistance - and provide a mechanism to
overcome ineffectiveness of existing and candidate drugs.
T
he main barrier for a drug to diffuse over the body and enter its target cell is the plasma membrane. This
barrier, enriched in sphingolipids and sterols, forms a dense hydrophobic sheet, almost impermeable for
hydrophilic compounds1,2. In drug design, therefore, amphiphilicity is an essential molecular requirement
(Lipinski’s rules). Consequently, the number of potential drug candidates from the vast chemical space is greatly
restricted3,4, and the efficacy of existing drugs is limited5,6. Indeed, poor accumulation of cytotoxic drugs in
tumour cells is a major limitation in cancer therapy, contributing to chemotherapy resistance.
Therefore, we questioned whether the membrane barrier function can be modulated in order to specifically
enhance drug traversal and increase its therapeutic window. As this approach should be systemically applicable, we
rationalized that the underlying mechanism requires concerted action with the drug molecule (instead of permea-
bilization for any compound). Doxorubicin is a stereotypical amphiphilic compound, whose membrane traversal
is among the best characterized: the molecule’s hydrophobic anthraquinone inserts into lipid bilayers sponta-
neously. Membrane translocation (flip-flop) of its hydrophilic daunosamine sugar, however, is slow and energet-
ically unfavorable7. In the clinic, doxorubicin is widely used as an anti-cancer agent, but in various situations
optimal efficacy is lacking. A long-circulating formulation, 100-nanometer pegylated liposomes (Doxil/CaelyxH),
was developed to counteract the rapid plasma clearance of the free drug8. The liposomal entrapment significantly
reduced toxicity (e.g. life-threatening cardiac failure), however failed to improve efficacy9.
The short-chain sphingolipid analogues N-hexanoyl-sphingomyelin and N-octanoyl-glucosylceramide (GC)
strongly enhance the intracellular accumulation of doxorubicin10, which we found not to be due to trivial
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Here, we develop a paradigm of facilitated drug-membrane trans-
location based on defined lipid analogues; the mechanism is eluci-
dated at molecular detail. Moreover, plasma membrane targeting, by
systemic co-administration of GC, widens the therapeutic window of
doxorubicin and overcomes multi-drug resistance.
Results
Membrane traversal of doxorubicin is facilitated by defined
truncated phospho- and glycolipids. We previously demonstrated
that GC acts at the level of the plasma membrane to enhance
doxorubicin accumulation in the cell, but not by inhibition of
ATP-dependent drug efflux pumps11. We first questioned whether
GC acts entirely independent onmembrane proteins. To that end, we
developed a doxorubicin translocation assay using model mem-
branes of well-defined lipid compositions in absence of proteins
(Fig. S1A–D). In liquid-disordered palmitoyl oleoyl phosphatidyl-
choline (POPC)/cholesterol (CH) membranes, incorporation of GC
significantly decreased doxorubicin translocation half-time (p ,
0.05) (Fig. 1A). The effect of GC was even more pronounced in
entirely liquid-ordered di-palmitoyl phosphatidylcholine (DPPC)/
sphingomyelin (SM)/CH membranes, which by themselves are
most impermeable for doxorubicin (Fig. 1A). In a POPC/CH/SM
composition, where the liquid-disordered phase co-exists with
liquid-ordered (rigid) domains, like in plasma membranes1, the
overall effect of GC was intermediate (Fig. S1E). These data show
that lipid organization of the membrane, independent of proteins,
determines the degree of GC-enhanced doxorubicin translocation.
We next determined the molecular requirements of the lipid ana-
logues to facilitate membrane traversal of doxorubicin. Using BAEC
cells, we first compared the effect of GC with that of other short-
chain (phospho) lipids. While di-myristoyl-phosphatidylcholine
(PC) only minimally affected the intracellular accumulation of
doxorubicin over 1 hour, di-nonanoyl-PC substantially elevated this
accumulation in a dose-dependent manner, similar to GC (Fig. 1B).
We next varied in a series of sphingo- and glycerophospholipids the
total aliphatic chain volume (i.e. the two acyl chains in PC, or acyl
plus sphingosine hydrocarbon chain in sphingolipids) and the head-
group size, thus ranging from a strongly conical to an entirely
cylindrical molecular geometry (see for definition of these geomet-
ries ref. 12). Fig. 1C shows that 25–27 carbons were optimal for
Figure 1 | Short-chain glycero- and sphingolipids facilitate doxorubicin-membrane traversal, depending on (A) membrane biophysical environment,
(B, C) total acyl chain length, and (C) lipid headgroup size. (A). Doxorubicin translocation over liquid-ordered (DPPC: SM: Chol, 25251molar ratio) or
liquid-disordered (POPC:Chol, 753 molar ratio) DNA-enclosed large unilamelar vesicles was determined in a fluorescence quenching assay (see
Supplemental). GC significantly reduced translocation half-time (K(translocation) (in seconds; SEM, n 5 3; p, 0.05). (B). Confluent BAEC cells were
pre-incubated for 15 min with short-chain sphingolipid (GC) or phosphatidylcholines (PC 950/950 and PC 1450/1450), and doxorubicin was applied
for 60 min. Intracellular doxorubicin accumulation was quantified (% of control, no lipid added) (SD, n 5 5). (C). Doxorubicin accumulation in BAEC
cells is plotted against the total hydrocarbon chain length (solid lines) at constant headgroup size (180 Da, phosphocholine or glucose); or against head
group size at constant total chain length of 24–26 carbons (dashed line), using C6-Cer (17 Da; OH-group), C8-Cer-1-P (95 Da), C6-SM (184 Da),
C8-LacCer (342 Da) (headgroup size in brackets); (mean, SD, n 5 5).
www.nature.com/scientificreports
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sphingolipids, whereas around 22 carbons appearedmost effective in
case of glycerophospholipids. The shift of the optimum peak is well
explained by the 3 carbons in the glycerol backbone of the glycer-
ophospholipids.
With respect to the hydrophilic head group, at a constant total
sphingolipid chain length of 24–26 C atoms, a minimum size of
180 Da was required for optimal doxorubicin accumulation
(Fig. 1C, Table S1). Together, our findings indicate that analogues
of natural lipids as defined by molecular geometry, are capable of
enhancing doxorubicin traversal over preferentially the liquid-
ordered lipid (raft) constituent of the plasma membrane.
Short-chain lipids assemble a transient membrane channel, faci-
litating doxorubicin traversal. The mechanism behind facilitated
doxorubicin traversal by short-chain lipids, and the contribution of
the drug molecule was investigated in silico using molecular dyna-
mics (MD) simulations. This technique provides detailed insight in
the behavior and interaction of individual molecules in lipid
bilayers13. Lipid bilayers were modeled at atomic detail in the pre-
sence or absence of 20% short-chain di-octanoyl-phosphatidylcholine
(PC 850/850; DOctPC). In line with experimental data14, doxorubicin
insertion and translocation over the membrane caused disordering of
the local lipid and acyl chain organization (Fig. 2A, Movie S1). The
presence of DOctPC caused a visible broadening and stabilization of
suchmembrane perturbation, assembling a transient lipid channel for
doxorubicin traversal. This DOctPC-mediated gateway afforded
substantial solvation of doxorubicin (its daunosamine sugar in
particular) within the lipid bilayer core, which involved lipid
headgroups lining the pore’s lumen and water molecules remaining
associated with the sugar moiety (Fig. 2B, Movie S1).
Free energy landscapes were obtained for the translocation of
doxorubicin across the lipid bilayers (Fig. 2C). Binding from the bulk
phase (.3.0 nm distance to the center of the lipid bilayer) to the
membrane surface (1.5–2.5 nm) is energy-favorable, by more than
225 kJ/mol, and indifferent for the presence of the short-chain
lipids. Translocation of doxorubicin across the bilayer center
(0.0 nm), on the other hand, surmounts an energy barrier of
45 kJ/mol for pure DPPC bilayers. This net energy barrier of
20 kJ/mol is in good agreement with reported data7. The presence
of the short-chain lipids significantly reduced the net energetic bar-
rier almost two-fold, by 7.8 kJ/mol (Fig. 2C).
We next determined the distribution of the DOctPC in the mem-
brane in relation to the position of doxorubicin. When doxorubicin
localized at the water-bilayer interface (membrane surface), no
Figure 2 | Short-chain phosphatidylcholines dynamically assemble into a molecular gateway for doxorubicin. (A), (B) Snapshots of simulations of a
pure DPPC bilayer (A) or a 451 DPPC:DOctPC bilayer (B). Doxorubicin was localized at the center of the bilayer by a harmonic potential. During
doxorubicin traversal, the short-chain lipids assemble a transient membrane channel. Doxorubicin is in red, water in blue, DPPC in yellow and DOctPC
in green; lipid headgroups are represented by a single bead at the phosphorus position. (C) The energetic barrier for doxorubicin translocation is reduced
by the short-chain lipids. Potential of mean force for doxorubicin as a function of the distance to the center of the membrane. Pure DPPC (red) or
DPPC:DOctPC (451) (green) bilayers; 6SD (shaded bands). (D), (E) Radial distribution for DOctPC (green line), relative to the doxorubicin position
(D) DPPC (orange line) is plotted as a control. In the top plot, doxorubicin located in the bilayer center, showing an enrichment of the DOctPC in the
vicinity of doxorubicin. The bottom plot represents the situation where doxorubicin localizes at the position of minimal membrane disturbance (water-
lipid bilayer interface), which showed absence of co-localization for DOctPCwith doxorubicin. (E) Corresponding volumes of occupancy (.10%) over a
120 ns time period. Doxorubicin in red, DOctPC in green, DPPC in translucid gray and water in blue.
www.nature.com/scientificreports
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preferred association with the short-chain lipids was observed
(Fig. 2D, lower panel). In contrast, when doxorubicin positioned in
the bilayer hydrophobic core, the short-chain lipids self-assemble in
its vicinity, adapting to doxorubicin (Fig. 2D, upper panel). The
notion that doxorubicin triggered channel formation was supported
experimentally, as short-chain lipids without doxorubicin did not
affectmembrane permeability andGC instead significantly stabilized
the membrane in an erythrocyte lysis assay (Fig. S2).
To further elucidate the self-assembling behavior of the short-
chain lipids, the space occupancy of the different molecules was
averaged over a time period of 120 ns, as shown in Fig. 2E (see also
Movie S2). Short-chain lipids preferentially twisted around the dox-
orubicin molecule and localized at the curvature of the channel. The
data show that self-assembly of short-chain lipids, triggered by dox-
orubicin’s infringement of normal lipid order, forms a transient
channel for the doxorubicin to traverse the membrane.
GC improves doxorubicin therapy and overcomes multi-drug
resistance in a heterogeneous GEM mammary tumour popu-
lation. As the above-described mechanism of membrane channel
formation is unrelated to drug resistance mechanisms involving
transporter proteins, we predicted that the lipid channels would
thus be able to counteract unresolved conditions of multi-drug
resistance. The WAPcre;EcadF/F;p53F/F (WEP) mammary tumour
model is a genetically engineered mouse (GEM) model that closely
mimics human invasive lobular breast carcinoma (ILC)15,16. To
characterize the drug sensitivity of the Ecad2/2;p532/2 WEP tu-
mours, we set up a mouse clinical trial by transplanting series of
individual WEP tumours into syngeneic recipient female mice.
Thus, a heterogeneous population of mammary tumour-bearing
mice was established, albeit within the limits of a defined, clinically
relevant breast cancer subtype (ILC). Mice with tumours of 200 mm3
were selected for treatment at maximum tolerated dose and
randomized against untreated controls. Conventional chemothe-
rapeutics (doxorubicin, docetaxel, topotecan, cisplatin) were
administered as well as the poly(ADP-Ribose) Polymerase (PARP)
inhibitor olaparib.
The large variations (SEM), already evident from the control
group, reflect the inter-individual heterogeneity characteristic for
the set-up (Fig. 3). Although some of the mice responded to cisplatin
therapy, overall these tumours appeared resistant towards chemo-
therapy, and to (free) doxorubicin in particular (Fig. 3).
We next investigated whether the induction of transient mem-
brane channels by GC would sensitize to doxorubicin therapy. As
GC in its free form is not water soluble, GC was co-formulated with
liposomal doxorubicin (LDox GC), without affecting the main phar-
maceutical parameters of the carrier17. Due to the outer PEG shield-
ing, the liposomes do not directly interact or fuse with cells8.
However, GC transfers from the liposomes via the aqueous phase
into the cell membrane (ref. 18, Fig. S3), thus remaining available to
the tumour cell membrane. Cell lines were derived from untreated
WEP Ecad2/2;p532/2 mammary tumours. Pre-incubation of these
WEP cell cultures with free GC elevated intracellular doxorubicin
accumulation in a GC dose-dependent fashion (Fig. 4A). We subse-
quently tested liposomal doxorubicin with and without 10 mol% GC
incorporated into its liposome bilayer on theWEP cells. LDox was of
the same composition as commercial CaelyxH (DoxilH) used in the
clinic. In line with its clinical features, LDox poorly delivered its
contents into the WEP cells, even after 24 hours incubation. In con-
trast, LDox GC established substantial intracellular doxorubicin
levels, an 8-fold increase over conventional LDox (Fig. 4B, C), and
the increased intracellular doxorubicin accumulation correlated with
improved cytotoxicity (Fig. 4D). As a control, empty liposomes of the
same lipid composition but without doxorubicin showed no cyto-
toxicity at all in the same concentration range for either formulation
(data not shown). Also in other WEP cell lines a similar gain of
cytotoxicity by LDox GC was observed, up to EC50 values obtained
by free doxorubicin (Table S2).
After establishing efficacy in the WEP cultures in vitro, we
assessed therapy response in the GEM model, using the clinical
trial set-up, as described above. The clinically used doxorubicin
formulations free doxorubicin (fDox) and conventional liposomal
doxorubicin (LDox) were administered at MTD, LDox GC was
applied at equidose to LDox (10 mg/kg), while untreated tumours
served as control. As depicted in Fig. 5A, LDox (without GC)
generated an initial anti-tumour effect, more so than free doxor-
ubicin (fDox), but tumours finally progressed despite additional
dosing in either group. However, when GC is present (LDox GC;
10 mg/kg) a sustained inhibition of tumour progression was
observed. At day 21 of treatment in the LDox GC group, tumour
size was significantly reduced over LDox (p , 0.05), by two-fold
(Fig. 5A).
We subsequently analyzed the overall survival of the different
treatment cohorts. The clinically used doxorubicin formulations
(LDox and fDox) did not result in a significantly extended survival
over the control group. Importantly, LDox GC was the only inter-
vention that prolonged overall survival significantly over untreated
controls (p 5 0.001). Median survival extended from 11 days to 30
days (Fig. 5B). A separate study in a homogeneous tumour cohort,
established from a single WEP donor tumour (CDB212) randomly
selected from the population a priori, further underlined these results
(Fig. S4).
After study exit, all major organs were collected and the samples
were blinded for investigation by veterinary pathologists. The LDox
GC group revealed minimal normal tissue effects; no additional tox-
icities were discernable as compared to the other doxorubicin for-
mulations. In all groups, the most prevalent anomaly was depleted
erythropoiesis, (Fig. 5C, right panels) in bonemarrow (upper panels)
and spleen (lower panels), as compared to a healthy tumour-free
(FVB 3 129/Ola) F1 mouse (left panels). In addition to tumour-
induced anemia, enforcement of this pathology by doxorubicin is a
well-known adverse effect, also in the human situation19,20. Notably,
for LDox GC this normal tissue effect was less frequent, as compared
to the LDox treated group (Fig. 5D). In the LDox GC cohort, the
incidence of reduced erythropoiesis appeared not significantly ele-
vated, compared to untreated controls (Chi-square test: p 5 0.41), in
contrast to the LDox treatment (Chi-square test: p 5 0.036). Overall,
we conclude that GC counteracts chemotherapy resistance in a
Figure 3 | Ecad2/2;p532/2 GEM mammary tumours are multi-drug
resistant. After orthotopic transplantation of a population of spontaneous
tumours from WAPcre;EcadF/F;p53F/F mice, treatment was started with
the indicated cytostatic drugs when tumour size reached 200 mm3, all at
maximum tolerated dose (MTD); or mice were left untreated as controls.
(Mean, SEM, n 5 5).
www.nature.com/scientificreports
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clinically relevant tumour model, greatly improving efficacy at
reduced bone marrow and spleen toxicity.
GC elevates intracellular doxorubicin accumulation in the GEM
mammary tumour, while reducing normal tissue exposure. In
order to further elucidate the observed reduced toxicity and to
shed more light on the pharmacokinetics of LDox GC, doxoru-
bicin plasma profiles were determined (CDB212 cohort). Evi-
dently, the sustained circulation time of LDox was preserved upon
GC co-formulation (Fig. 6A), while doxorubicin plasma levels
steeply declined during the first two hours. Non-compartmental
kinetic analysis showed that the distribution rate in this first phase
increased 4-fold as compared to LDox without GC (Table S3), which
mainly accounted for the reduced systemic doxorubicin levels.
Overall, plasma AUC was reduced 3-fold (p , 0.05) and residual
circulating doxorubicin (96 hours after administration) was de-
creased 8-fold (p , 0.05) by GC co-administration.
Once inside the cell, doxorubicin strongly binds DNA in the nuc-
leus (75% of the total intracellular fraction)21. We investigated the
intracellular accumulation of doxorubicin in the mammary tumour
using the CDB212 cohort. In order to distinguish intracellular dox-
orubicin from the total tissue, we optimized a nucleus isolation pro-
tocol, minimizing doxorubicin carryover from the liposomes to less
than 0.5%. The biodistribution was analyzed for each doxorubicin
formulation over a time period that covered.90% plasma AUC (96
hours for both liposomal, 4 hours for the free doxorubicin).
fDox accounted for marginal total tumour as well as intracellular
doxorubicin accumulation (Fig. 6B). Total tumour levels by LDox
were high, but doxorubicin poorly entered the tumour cell (,15% of
total tumour AUC), in line with its clinical limitations22. The accu-
mulation of liposomes in the tumour tissue is attributed to ‘Enhanced
Permeability and Retention’23, an effect observed for both liposomal
formulations (Fig. S5). LDox GC however, at lower total tumour
tissue level than LDox, strongly elevated intracellular doxorubicin
(40% of total AUC), increasing the total intracellular accumulation
by two-fold (p, 0.05) (Fig. 6B). Contrary to the tumour – the heart,
liver and spleen showed comparable or even slightly (10–20%)
reduced doxorubicin accumulation by GC co-administration
(Fig. 6B, Table S4). Total tissue accumulation in the latter organs,
active in clearing liposomal particles from the blood stream (reticu-
loendothelial system), was strongly reduced for LDox GC (Fig. 6B) –
in concordance with its lower plasma levels (Fig. 6A). The decreased
doxorubicin accumulation in the spleen is moreover in good agree-
ment with the lower incidence of erythropoietic depletion by LDox
GC (Fig. 5C, D).
We investigated whether there was a preference of GC mediated
drug gateways for the tumour cell membrane. Of spleen, heart and
tumour we determined the fraction doxorubicin that finally passes
the membrane, ending up inside the cell, over the above mentioned
time courses. The effect of GC appeared strongest on the tumour cell
membrane (Fig. S6A). We confirmed this observation in vitro on
various cell cultures (Fig. S6B).
Discussion
Membrane translocation strongly delineates the compounds that,
from the vast chemical space, can potentially act as a bioactive drug.
Figure 4 | GC enhances cellular accumulation of doxorubicin in mouse mammary tumour (WEP) cells and restores cytotoxicity. (A–C) Intracellular
doxorubicin accumulation inWEP cells in presence or absence of GC.WEP3 cell cultures were derived fromEcad2/2;p532/2mammary tumours andwere
pre-incubated with free GC from an ethanol solution, followed by 1 hour free doxorubicin incubation (50 mM) (A) Intracellular doxorubicin
accumulation was quantified by fluorometry on cell lysates and normalized against control (no GC pre-incubation). (B) Doxorubicin accumulation in
WEP3 cells incubated for 24 hours with liposomal doxorubicin plus GC (LDox GC), or conventional doxorubicin liposomes (LDox) as control.
(C) Fluorescence micrographs of doxorubicin, taken at equal exposure times, on (live) WEP3 cells immediate after 24 hours incubation with LDox GC
(right panel) or LDox (left panel) (10 mM). (D) WEP3 cell viability after 24 hour incubation with LDox GC or LDox. Cells were kept in culture for an
additional 48 hours. Viability was then assessed by the metabolic XTT assay. Data are expressed as mean percentages to untreated cells (SD, n 5 6). As a
control, incubation with the same liposomes but devoid of doxorubicin did not affect cell viability.
www.nature.com/scientificreports
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Moreover, it hampers efficacy of existing drugs. Poor intracellular
accumulation accounts for situations of suboptimal or ineffective
therapy, including therapy resistance24. We here describe a well-
defined paradigm for enhancing drug-membrane translocation
and subsequent elevated intracellular accumulation. Amphiphilic
drug molecules by themselves impose strong distortion upon the
natural lipid assembly, when traversing the membrane. We dem-
onstrate that during this process, the assembly of short-chain lipids
is triggered around doxorubicin in a short time frame, much quicker
(ns) than that of doxorubicin-membrane translocation (ms)25. Such
spatiotemporal enrichment of the truncated lipids in vicinity of the
drug favors local membrane curvature and hence allows transient
channel formation of a size just fitting for doxorubicin to translocate.
GC thus on its own does not permeabilize themembrane, and instead
acts in rapid concert with the drug. After acceleration of the trans-
location process, channel disassembly can occur as soon the drug has
left the membrane to bind its intracellular target or further diffuse
through the body.
Liquid-disordered and liquid-ordered phases coexist in plasma
membranes dependent on cell type and conditions26. The anti-cancer
drug doxorubicin binds strongest to the liquid-ordered lipid phase of
membranes27. Strikingly, the doxorubicin uptake-enhancing effect of
GC ismost prominent in the liquid-ordered (lipid raft) environment,
where spontaneous doxorubicin traversal is slowest. In all tumour
cells tested thus far, but not in most normal cells, lipid analogues
(such as GC) effectively facilitated doxorubicin traversal across the
plasma membrane. Characteristically, the outer leaflet of the plasma
membrane is indeed enriched in sphingolipids and sterols1, which
form the liquid-ordered phase. One could therefore hypothesize that
tumour cells are particularly rich in liquid-ordered plasma mem-
brane outer leaflets, when compared to cells of e.g. heart, spleen
and liver, as lipid compositions vary significantly between tissues
and cell types28–30. However, systematic lipidomics information is
lacking, and in particular at such subcellular detail. Advanced lipi-
domics analyses (e.g. by imaging mass spectrometry) are needed to
further elucidate (subtle) differences among cell types, or those
associated with malignant transformation30–32.
Overall, rational design of lipid analogues, medicinal chemical lipid-
analogue structure optimization, and systematic high-throughput
screening are approaches that are suitable for identifying selected
action on cell type and the drug combination of interest. For tumour
cells, we are currently employing this strategy to improve efficacy of
other anti-cancer drugs, such as mitoxantrone, which is clinically
hampered by inadequate delivery and bioavailability.
Conventional therapy with free or liposomal doxorubicin has its
limitations: Free doxorubicin shows life-threatening cardiotoxicity
and is rapidly eliminated from the body22. Conventional liposomal
doxorubicin (CaelyxH) stays sufficiently longer in circulation but is
hampered by poor intracellular delivery of the drug9,22. A strategy of
concomitant GC membrane targeting combines the advantages of
Figure 5 | Co-administration ofGCprovides superior anti-tumour efficacy inmulti-drug resistantmammary tumours. (A)GC re-sensitize tumours to
doxorubicin therapy in a heterogeneous tumour population; in the LDoxGC cohort, average tumour size (6SEM, n5 9) was significantly reduced at day
21, compared to LDox (without GC) (p , 0.05). Arrows indicate time points of drug dosing. (B) LDox GC is the only treatment that significantly
prolongs median survival by 2.7-fold over untreated control (p, 0.001). (C) H&E stained specimen of bone marrow (C, upper) and spleen (C, lower).
Doxorubicin treatment severely depletes erythropoietic cells (dark-blue stained) (C, right), compared to control tissue (C, left) (bars 20 mm).
(D) Incidence (%) of reduced erythropoiesis in numbers of organs per treatment group. Compared to control (6/30), depletion of erythropoiesis was seen
in fDox (12/24) and LDox (18/32) groups, but less for GC co-administration (12/30).
www.nature.com/scientificreports
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these two clinical formulations (Fig. 7). While long-circulation is
preserved by liposomal entrapment, GC establishes intracellular
delivery into the tumour cells. Moreover, towards normal tissues
doxorubicin exposure is unaffected or reduced, and plasma levels
as well as erythropoeitic toxicity attenuate; resulting in an increase
of the therapeutic ratio.
Liposomal encapsulation protects from life-threatening cardio-
toxicity. As was evident from phase III clinical trials, this beneficial
effect is rather independent of pharmacokinetics of the particular
liposomal formulation9,33. In contrast, palmar-plantar erythrody-
sesthesia (PPE), the dose-limiting toxicity of current liposomal dox-
orubicin (Caelyx) therapy, strongly correlates to pharmacokinetics,
in particular to long-term doxorubicin plasma level34, which was 8-
fold reduced by the co-formulation of GC.
We used Ecad2/2;p532/2 mouse mammary tumours that, like
many other spontaneous GEM tumours, are therapy resistant and
closely resemble the human counterpart15,16. Uptake of free doxor-
ubicin by these tumours was extremely low. LDox GCmay challenge
therapy resistance of these tumours in three ways. First, the lipo-
somes accumulate in the tumour over time, a phenomenon known as
Enhanced Permeability and Retention23, thereby reaching substan-
tially higher doxorubicin levels in tumour tissue than with free dox-
orubicin. Secondly, the short-chain lipid enhances the doxorubicin
flux into the tumour cell from the interstitial fluid where the lipo-
somes leak their content. Thirdly, the efficacy of GCmay be enforced
by the fact that multidrug-resistance (MDR) proteins (such as the
ABCB1 and ABCC1 drug efflux transporters) are lipid exporters that
expel short-chain GC (but not long-chain GC) efficiently to the outer
bilayer leaflet35, once it has reached the intracellular side after co-
flipping with doxorubicin. The short-chain lipid is thus continuously
recycled back to the cell surface, ready to aid new doxorubicin part-
ners in traversing the membrane. This study highlights a critical role
of the cellular plasma membrane in cases of drug resistance.
In summary, drug-triggered molecular assembly of transient
channels facilitates drug traversal over the plasma membrane. GC-
mediated channels preferentially target the tumour cell membrane to
strongly elevate intracellular doxorubicin accumulation.While redu-
cing systemic exposure, LDox GC increases anti-tumour efficacy and
overcomes multi-drug resistance.
Methods
Doxorubicin uptake. Serum-starved BAEC cells were pre-incubated with short-
chain lipids from ethanol for 15 minutes after which free doxorubicin was applied for
1 hour. Intracellular doxorubicin was quantified and corrected for protein content.
Figure 6 | GC reduces systemic exposure to doxorubicin, while elevating
intracellular tumour accumulation. (A) Semi-logarithmic doxorubicin
plasma concentration-time curve after i.v. injection of LDox GC, LDox
and fDox. Plasma levels (mM) were expressed per injected dose (mean,
SEM, n 5 3). (B) Intracellular and total tissue doxorubicin in the tumour
and the heart. Data are expressed as the AUC per gram tissue, per gram
injected doxorubicin. GC elevates intracellular drug accumulation in the
tumour by a factor two (p , 0.05). (Mean, SEM, n 5 12).
Figure 7 | Increased therapeutic window of doxorubicin by GC-mediated
membrane modulation. From the liposomal vehicle, fDox (red) and free
GC (green) leak into the interstitial fluids and partition into the (tumour)
cell membrane (top cartoon). fDox plasma peak levels are much reduced
by liposomal formulation (thinner red arrows left of membrane), but
doxorubicin entry in the tumour cell is low in absence of GC (middle
cartoon). GC, when co-inserted into the membrane, enhances membrane
traversal of doxorubicin (thickened red arrow right of membrane) and
thus, accumulation into tumour cell DNA. The relative effects of the three
doxorubicin formulations on blood circulation time, tumour cell nucleus
incorporation and sparing of normal tissues are summarized in the table.
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Assay for doxorubicin translocation across lipid vesicles. By reversed-phase
evaporation large unilaminar vesicles (LUV) were prepared to enclose DNA. The
DNA-LUVs were injected into a doxorubicin solution (50 mM) and doxorubicin
fluorescence was monitored in a spectrofluorometer. The quenching of fluorescence
(Q) over time was fitted according to Q(t) 5 Q(max)t/(K(translocation) 1 t), where
K(translocation) is the translocation half-time (sec). The maximal quenching
(Q(max)) was determined after releasing all DNA by LUV disruption.
Molecular dynamics of doxorubicin translocation. Simulations of doxorubicin
translocation across a membrane containing 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) or DPPC and 1,2-dioctanoyl-sn-glycero-3-phosphocholine
(DOctPC) were carried out using GROMACS 4.5.4 package and 53A6 GROMOS
united-atom force field. The center of mass of doxorubicin was positioned at different
distances to the bilayer center, as indicated, using a harmonic restraint in the direction
of the bilayer normal. Free energy profiles were obtained after integrating the force of
the restraining potential at each depth.
GEM mammary tumour model and therapeutic intervention. Ecad2/2;p532/2
mammary tumours, generated in WAPcre;EcadF/F;p53F/F (WEP) mice were
orthotopically transplanted in syngeneic wild-type mice. The first drug dose was
administered when the tumour reached 200 mm3. The tumour volume (in mm3) was
calculated using the formula: 0.5 3 length 3 width2. Treatments (MTD): Olaparib:
daily 50 mg/kg i.p.; docetaxel: weekly 25 mg/kg i.v.; cisplatin: once every two weeks
6 mg/kg i.v.; topotecan daily 4 mg/kg i.p.; free doxorubicin: weekly 5 mg/kg i.v.;
LDox (conv): weekly 10 mg/kg i.v.; LDox GC: weekly 10 mg/kg i.v. Mice were
sacrificed when tumour volume exceeded 1500 mm3 or body weight declined below
80% of its initial value. Tissues, includingmammary fat pad (tumour), sentinel lymph
node, lung, liver, heart, bone marrow, thymus, spleen, kidneys and GI-tract, were
blinded, fixed and H&E stained followed by pathological investigation. All mouse
experiments were performed in accordance withDutch law and regulatory guidelines.
The ‘Dier Experimentele Commissie’ of the NKI was involved in experimental design
and approved all experiments prior to study start.
Plasma kinetics. From mice with the CDB212 tumour (350 mm3) blood samples
were drawn by tail-clipping and collected in heparinized tubes. Plasma was obtained
and doxorubicin was quantified by HPLC and expressed per gram injected
doxorubicin.
Doxorubicin incorporation in tissues and cell nuclei. Mice with orthotopical
CDB212 tumours were i.v. injected with doxorubicin when primary tumour was
350 mm3. At t 5 4, 24, 48 and 96 hours (LDox GC and LDox) or at t 5 0.5, 1 and 4
hours (fDox) 3 mice were sacrificed. Body perfusion was immediately performed
(5 min, 100 mmHg) via the left ventricle of the heart. Heart, liver, spleen and tumour
tissue were homogenized in ice-cold nuclear isolation medium. From half of the
sample nuclei were isolated by sucrose density centrifugation. Doxorubicin was
quantified byHPLC. Data were corrected for tissue weight and doxorubicin dose, and
if applicable, nuclei isolation yield.
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